Silence Therapeutics develops RNA interference (RNAi) medicines that use short interfering RNA (siRNA) to silence disease-associated genes without permanently altering DNA. Its proprietary mRNAi GOLD platform combines siRNA with GalNAc delivery chemistry to target liver cells and other selected tissues. The company advances clinical and partnered programs aimed at conditions with limited treatment options, focusing on precision gene-silencing rather than symptom management.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.2 | — | -27.4 | — |
| Q3 2025 | 0.2 | — | -21 | — |
| Q4 2025 | 0 | — | -11.8 | — |
| Q1 2026 | 0.4 | — | -15 | — |
| Q2 2026 | 0 | -100% | -12.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pacific Biosciences of California, Inc. (PACB), LightPath Technologies, Inc. (LPTH), The Honest Company, Inc. (HNST), Elevra Lithium Limited (ELVR), Backblaze, Inc. (BLZE), Valneva SE (VALN)